Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
110
archived clinical trials in
Genital Herpes

A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Spokane, WA
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
La Crosse, WI
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
La Crosse, WI
Click here to add this to my saved trials
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Milwaukee, WI
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Waukesha, WI
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Waukesha, WI
Click here to add this to my saved trials
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated:  12/31/1969
GSK Investigational Site
mi
from
Buenos Aires,
A Study Comparing Daily Treatment With Valaciclovir To Placebo For Suppression Of Herpes Simplex Virus HSV-2 Genital Herpes In Newly Diagnosed Patients. VALTREX® Tablet is a Trademark of the GlaxoSmithKline Group of Companies.
An International, Randomized, Double-Blind, Placebo-Controlled, Multicenter, 6-Month Study of the Efficacy and Safety of Valtrex 1g QD vs. Placebo for the Suppression of HSV-2 Genital Herpes in Newly Diagnosed Immunocompetent Patients
Status: Enrolling
Updated: 12/31/1969
GSK Investigational Site
mi
from
Buenos Aires,
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Alabama Vaccine Research Clinic; University of Alabama at Birmingham
mi
from
Birmingham, AL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Alabama Vaccine Research Clinic; University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
QPS Broward Research
mi
from
Hollywood, FL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
QPS Broward Research
mi
from
Hollywood, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
QPS Miami Research Associates
mi
from
South Miami, FL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
QPS Miami Research Associates
mi
from
South Miami, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Comprehensive Clinical Trials
mi
from
West Palm Beach, FL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Comprehensive Clinical Trials
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Univ of Illinois
mi
from
Chicago, IL
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Univ of Illinois
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Indiana University Infectious Disease Research
mi
from
Indianapolis, IN
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Indiana University Infectious Disease Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Heartland Research Associates, LLC
mi
from
Wichita, KA
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Central Kentucky Research Associates, Inc.
mi
from
Lexington, KY
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
The Center for Pharmaceutical Research, P.C.
mi
from
Kansas City, MO
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Rochester Clinical Research Inc.
mi
from
Rochester, NY
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
University of North Carolina (UNC) Institute of Global Health and Infectious Diseases
mi
from
Chapel Hill, NC
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
University of North Carolina (UNC) Institute of Global Health and Infectious Diseases
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Clinical Research Associates
mi
from
Nashville, TN
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Clinical Research Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
University of Utah School of Medicine - Division of Infectious Diseases
mi
from
Salt Lake City, UT
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
University of Utah School of Medicine - Division of Infectious Diseases
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
Safety and Efficacy Study of Herpes Simplex Virus Type 2 (HSV-2) Therapeutic DNA Vaccine
A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial to Evaluate the Safety and Efficacy of Herpes Simplex Virus, Type 2 (HSV-2) Therapeutic DNA Vaccine in Adults With Symptomatic Genital HSV-2 Infection
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Medical Center for clinical research
mi
from
San Diego, CA
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Optimus Medical Group
mi
from
San Francisco, CA
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Optimus Medical Group
mi
from
San Francisco, CA
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
UNC Health
mi
from
Chapel Hill, NC
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
UNC Health
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Cincinnati Children's Hospital Medical Center
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
NW Dermatology and Research Clinic
mi
from
Portland, OR
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
NW Dermatology and Research Clinic
mi
from
Portland, OR
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Tekton Research
mi
from
Austin, TX
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Tekton Research
mi
from
Austin, TX
Click here to add this to my saved trials
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated:  12/31/1969
Univ of Washington
mi
from
Seattle, WA
Maintenance Dose Study of GEN-003 in Subjects With Genital Herpes Infection
A Randomized, Placebo-controlled, Double-blind Study to Assess the Efficacy and Safety of a Maintenance Dose of GEN-003 in Subjects With Genital Herpes Infection
Status: Enrolling
Updated: 12/31/1969
Univ of Washington
mi
from
Seattle, WA
Click here to add this to my saved trials
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated:  11/5/2012
Indiana University School of Medicine, IU Infectious Diseases Research
mi
from
Indianapolis, IN
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated: 11/5/2012
Indiana University School of Medicine, IU Infectious Diseases Research
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated:  11/5/2012
Westover Heights Clinic
mi
from
Portland, OR
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated: 11/5/2012
Westover Heights Clinic
mi
from
Portland, OR
Click here to add this to my saved trials
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated:  11/5/2012
University of Texas Health Science Centre, Center for Clincial Studies
mi
from
Houston, TX
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated: 11/5/2012
University of Texas Health Science Centre, Center for Clincial Studies
mi
from
Houston, TX
Click here to add this to my saved trials
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated:  11/5/2012
University of Washington, Virology Research Clinic
mi
from
Seattle, WA
Safety and Efficacy Comparator Trial of a New Drug Against Genital Herpes
A Double-blind, Double Dummy, Randomized Crossover Trial to Compare the Effect of AIC316 100 mg Once Daily Versus Valacyclovir 500 mg Once Daily on Genital HSV Shedding in HSV-2 Seropositive Adults.
Status: Enrolling
Updated: 11/5/2012
University of Washington, Virology Research Clinic
mi
from
Seattle, WA
Click here to add this to my saved trials
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission
Status: Enrolling
Updated:  7/2/2015
University of Washington Virology Research Clinic
mi
from
Seattle, WA
Effect of HSV-2 Suppressive Therapy on Sexual Behavior
Effect of Suppressive Therapy on Behavioral Determinants of HSV-2 Transmission
Status: Enrolling
Updated: 7/2/2015
University of Washington Virology Research Clinic
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection
Status: Enrolling
Updated:  10/18/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Study of the Safety of a Particular Herpes Vaccine in Adults With or Without Herpes Infection
Phase I Study of the Safety of Replication-Defective Herpes Simplex Virus-2 Vaccine, HSV529, in Adults Aged 18 to 40 Years With or Without HSV Infection
Status: Enrolling
Updated: 10/18/2017
National Institutes of Health Clinical Center, 9000 Rockville Pike
mi
from
Bethesda, MD
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Birmingham, AL
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Phoenix, AZ
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Phoenix, AZ
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Tucson, AZ
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Tucson, AZ
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Los Angeles, CA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Sacramento, CA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Sacramento, CA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
San Diego, CA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Westlake Village, CA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Westlake Village, CA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Denver, CO
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Denver, CO
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Boynton Beach, FL
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Miami, FL
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Atlanta, GA
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Indianapolis, IN
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Indianapolis, IN
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Madisonville, KY
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Madisonville, KY
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Baltimore, MD
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Baltimore, MD
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Billings, MT
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Billings, MT
Click here to add this to my saved trials
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated:  12/1/2017
Clinical Research Facility
mi
from
Omaha, NE
A Study With ASP2151 in Subjects With Recurrent Episodes of Genital Herpes
A Phase II, Dose-Finding Study With ASP2151 in Subjects With Recurrent Episodes of Genital HErpes
Status: Enrolling
Updated: 12/1/2017
Clinical Research Facility
mi
from
Omaha, NE
Click here to add this to my saved trials